Cardiology

Subcutaneous ICDs reduce complications without compromising shock effectiveness

19 hours ago

Implantation of subcutaneous implantable cardioverter defibrillators (S-ICDs) results in fewer perioperative, lead-related complications without offsetting the effectiveness of ICD shocks, reveals a study. However, S-ICDs lead to more early postoperative pain and inappropriate shocks.

ADHD medication use carries no excess risk of cardiovascular diseases

Yesterday

Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.

IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients

Audrey Abella, Yesterday

In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.

Rivaroxaban + aspirin combo halves stroke risk in COMPASS

3-month rivaroxaban use safe, effective in \isolated DVT

Stephen Padilla, 2 days ago

Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.

1-year isometric exercise training improves BP management

2 days ago

Isometric exercise training (IET) appears to be a good long-term intervention in managing resting blood pressure (BP), reports a recent study. IET delivers clinically important, chronic BP adaptations in patients at risk of hypertension.

Left ventricular global longitudinal strain predicts death risk in aortic stenosis

2 days ago

In patients with moderate aortic stenosis (AS) and reduced left ventricular (LV) systolic dysfunction, LV global longitudinal strain (GLS) appears to be an independent indicator of mortality, a new study has found.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 04 Oct 2022

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

$Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum$

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients

Audrey Abella, 02 Dec 2022

Chinese herbal med cuts MACCE in STEMI, but questions remain

Elvira Manzano, 01 Dec 2022

Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.

CT angiography may increase potential recipients of EVT for acute ischaemic stroke

CT angiography may increase potential EVT recipients for acute ischaemic stroke

Roshini Claire Anthony, 27 Nov 2022

Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.

Lower all-cause death, fewer HF events with empagliflozin in acute HF

Roshini Claire Anthony, 25 Nov 2022

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Intensive BP-lowering a no-go after reperfusion in ischaemic stroke

Roshini Claire Anthony, 14 Nov 2022

An intensive blood pressure target (<120 mm Hg) should be avoided in patients who have undergone endovascular thrombectomy for acute ischaemic stroke (AIS) for large-vessel occlusion (LVO), results of the phase III ENCHANTED2/MT* trial showed.

First ESC Guidelines on managing cardiac toxicity related to cancer treatments

Roshini Claire Anthony, 09 Nov 2022

The inaugural European Society of Cardiology (ESC) Guideline on cardio-oncology, revealed at the ESC Congress 2022 in Barcelona, Spain, provides some much-needed information on the concurrent management of cancer and cardiovascular (CV) disease.